He, YanLing

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 361

Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study

Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R. (2008) · Current Medical Research and Opinion

Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cited by 147

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 99

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., et al. (2022) · Nature Medicine

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 75

Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment

Kallend, D., Stoekenbroek, R., He, Y., Smith, P. F., & Wijngaard, P. (2022) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 73

The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia

Luo, Z., Huang, Z., Sun, F., Guo, F., Wang, Y., Kao, S., Yang, G., Huang, J., Li, J., Zhao, S., et al. (2023) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 38

Translational Population‐Pharmacodynamic Modeling of a Novel Long‐Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia

Gosselin, N. H., Schuck, V. J. A., Barriere, O., Kulmatycki, K., Margolskee, A., Smith, P., & He, Y. (2023) · Clinical Pharmacology & Therapeutics

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 17